

FORM PTO-1449 (Modified)		Attorney Docket No.: 23070-099120US		Application No.: 09/071,953	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Claude F. Meares, <i>et al.</i>		ATTORNEY TO #7	
		Filing Date: September 27, 2000		Group: 1646	
Reference Designation			U.S. PATENT DOCUMENTS		
Examiner Initial	Document No.	Date	Name	Class	Sub-class
AA					
FOREIGN PATENT DOCUMENTS			DEC 18 2000		
	Document No.	Date	Country	Class	Sub-class
AB	WO 95/15979	06/15/95	PCT	C07K	1452
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
AC	M. Chinol, <i>et al.</i> , "Biodistribution in tumour-bearing mice of two <sup>90</sup> Y-labelled biotins using three-step tumour targeting," <i>Nuclear Medicine Comm.</i> , 18:176-182 (1997)				
AD	David A. Goodwin, <i>et al.</i> , "Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens," <i>J. Nucl. Med.</i> , 29:226-234 (1998)				
AE	David A. Goodwin, <i>et al.</i> , "Pretargeted immunoscintigraphy: Effect of hapten valency on murine tumor uptake," <i>J. Nucl. Med.</i> , 33:2006-2013 (1992)				
AF	D. J. Hnatowich, <i>et al.</i> , "Investigations of avidin and biotin for imaging applications," <i>J. Nucl. Med.</i> , 28:1294-1302 (1987)				
AG	H. P. Kalofonos, <i>et al.</i> , "Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: Preliminary communication," <i>J. Nucl. Med.</i> , 31:1791-1796 (1990)				
AH	Alexander L. Klivanov, <i>et al.</i> , "Blood clearance of radiolabeled antibody: Enhancement by lactosamination and treatment with biotin-avidin or anti-mouse IgG antibodies," <i>J. Nucl. Med.</i> , 29:1951-1956 (1988)				
AI	J. Ian Marsh, <i>et al.</i> , "Streptavidin and biotin as potential tumor imaging agents," <i>J. Nucl. Med.</i> , 29(5):728-729 (1988)				
AJ	Damon L. Meyer, <i>et al.</i> , "Kinetics of the dissociation of indium-(p-substituted-benzyl)ethylenediaminetetraacetic acid hapten analogues from the monoclonal anti-hapten antibody CHA255," <i>Bioconjugate Chem.</i> , 1:278-284 (1990)				
AK	Jeffrey T. Owens, <i>et al.</i> , "Mapping the promoter DNA sites proximal to conserved regions of $\sigma^{70}$ in an <i>escherichia coli</i> RNA polymerase-lacUV5 open promoter complex," <i>Biochemistry</i> , 37:7670-7675 (1998)				
AL	Jeffrey T. Owens, <i>et al.</i> , "Mapping the $\sigma^{70}$ subunit contact sites on <i>escherichia coli</i> RNA polymerase with a $\sigma^{70}$ -conjugated chemical protease," <i>Proc. Natl. Acad. Sci. USA</i> , 95:6021-6026 (1998)				
AM	G. Paganelli, <i>et al.</i> , "Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients," <i>Cancer Research</i> , 51:5960-5966 (1991)				
AN	G. Paganelli, <i>et al.</i> , "Monoclonal antibody pretargeting techniques for tumour localization: the avidin-biotin system," <i>Nuclear Medicine Comm.</i> , 12:211-234 (1991)				
AO	Dayton T. Reardan, <i>et al.</i> , "Antibodies against metal chelates," <i>Nature</i> , 316:265-268 (1985)				
AP	Bruno Robert, <i>et al.</i> , "Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor $\alpha$ ," <i>Cancer Research</i> , 56:4758-4765 (1996)				
AQ	Eric Rouvier, <i>et al.</i> , "Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens," <i>Horm. Res.</i> , 47:163-167 (1997)				
AR	B. Schechter, <i>et al.</i> , "Indirect immunotargeting of CIS-PT to human epidermoid carcinoma KB using the avidin-biotin system," <i>Int. J. Cancer</i> , 48:167-172 (1991)				
AS	Vladimir V. Sinitsyn, <i>et al.</i> , "Rapid blood clearance of biotinylated IgG after infusion of avidin," <i>J. Nucl. Med.</i> , 30:66-69 (1989)				
AT	Dwight R. Stickney, <i>et al.</i> , "Bifunctional antibody: A binary radiopharmaceutical delivery system for imaging colorectal carcinoma," <i>Cancer Research</i> , 51:6650-6655 (1991)				
AU	Fan Yuan, <i>et al.</i> , "Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies," <i>Cancer Research</i> , 51:3119-3130 (1991)				
EXAMINER	DATE CONSIDERED		3/26/02		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box




PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

## Complete if Known

Application Number	09/671,953	ATTACH
Filing Date	September 27, 2000	Y0
First Named Inventor	Meares, Claude F.	#8
Group Art Unit	1646	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	23070-099120	

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
LBP	AA	4,678,667 A		Meares, et al.	07/07/87	
	AB	4,722,892 A		Meares, et al.	02/02/88	
	AC	5,541,287 A		Yau, et al.	07/30/96	
	AD	5,747,654 A		Pastan, et al.	05/05/98	
	AE	5,789,554 A		Leung, et al.	08/04/98	
GA	AF	5,837,242 A		Holliger, et al.	11/17/98	

RECEIVED

MAY 31 2001

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner  
Signature

*[Handwritten Signature]*

Date  
Considered

3/26/02